drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00054 | DB10672 | 1,432 | 297 | [
"DDInter6",
"DDInter417"
] | Abciximab | Clove | Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (αv... | Clove allergenic extract is used in allergenic testing. | Minor | 0 | [
[
[
1432,
23,
297
]
],
[
[
1432,
25,
235
],
[
235,
62,
297
]
],
[
[
1432,
24,
578
],
[
578,
23,
297
]
],
[
[
1432,
25,
1564
],
[
1564,
... | [
[
[
"Abciximab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
]
],
[
[
"Abciximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
],
[
"Desirudin",
"{... | Abciximab may lead to a major life threatening interaction when taken with Desirudin and Desirudin may cause a minor interaction that can limit clinical effects when taken with Clove
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a minor int... |
DB00563 | DB09135 | 663 | 1,211 | [
"DDInter1174",
"DDInter967"
] | Methotrexate | Ioxilan | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Ioxilan is a tri-iodinated diagnostic contrast agent. Intravascular injection results in opacification of vessels in the path of flow of the contrast medium, permitting radiographic visualization of the internal structures of the human body until significant hemodilution occurs. | Major | 2 | [
[
[
663,
25,
1211
]
],
[
[
663,
63,
811
],
[
811,
24,
1211
]
],
[
[
663,
24,
674
],
[
674,
24,
1211
]
],
[
[
663,
24,
242
],
[
242,
... | [
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ioxilan"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metolazone"
],
[
"Metolazon... | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Metolazone and Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Ioxilan
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Trichlormethiazide a... |
DB00747 | DB00792 | 1,442 | 832 | [
"DDInter1647",
"DDInter1878"
] | Scopolamine | Tripelennamine | Scopolamine is a tropane alkaloid isolated from members of the _Solanaceae_ family of plants, similar to [atropine] and [hyoscyamine], all of which structurally mimic the natural neurotransmitter [acetylcholine].[A228423, A228763] Scopolamine was first synthesized in 1959, but to date, synthesis remains less efficient ... | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | Moderate | 1 | [
[
[
1442,
24,
832
]
],
[
[
1442,
24,
100
],
[
100,
63,
832
]
],
[
[
1442,
63,
508
],
[
508,
1,
832
]
],
[
[
1442,
63,
1594
],
[
1594,
... | [
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
]
],
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
... | Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine
Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Proma... |
DB09065 | DB15822 | 760 | 69 | [
"DDInter424",
"DDInter1504"
] | Cobicistat | Pralsetinib | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Pralsetinib, similar to the previously approved [selpercatinib], is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A219751, L15986] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers, including non-small... | Major | 2 | [
[
[
760,
25,
69
]
],
[
[
760,
25,
283
],
[
283,
24,
69
]
],
[
[
760,
64,
1213
],
[
1213,
24,
69
]
],
[
[
760,
63,
723
],
[
723,
24,
... | [
[
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pralsetinib"
]
],
[
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} ... | Cobicistat may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Pralsetinib
Cobicistat may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate inter... |
DB00975 | DB06603 | 1,317 | 39 | [
"DDInter573",
"DDInter1387"
] | Dipyridamole | Panobinostat | A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Major | 2 | [
[
[
1317,
25,
39
]
],
[
[
1317,
24,
578
],
[
578,
63,
39
]
],
[
[
1317,
63,
1560
],
[
1560,
24,
39
]
],
[
[
1317,
25,
4
],
[
4,
24,
... | [
[
[
"Dipyridamole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Dipyridamole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Tica... | Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase an... |
DB00443 | DB01185 | 251 | 155 | [
"DDInter195",
"DDInter759"
] | Betamethasone | Fluoxymesterone | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | An anabolic steroid that has been used in the treatment of male hypogonadism, delayed puberty in males, and in the treatment of breast neoplasms in women. | Moderate | 1 | [
[
[
251,
35,
155
]
],
[
[
251,
24,
1546
],
[
1546,
40,
155
]
],
[
[
251,
1,
175
],
[
175,
24,
155
]
],
[
[
251,
63,
443
],
[
443,
1,... | [
[
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluoxymesterone"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases w... | Betamethasone (Compound) resembles Fluoxymesterone (Compound) and
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Methyltestosterone and Methyltestosterone (Compound) resembles Fluoxymesterone (Compound)
Betamethasone (Compound) resembles Triamcinolone (Compound) and Triamc... |
DB12035 | DB13749 | 943 | 1,473 | [
"DDInter1641",
"DDInter1116"
] | Sarecycline | Magnesium gluconate | Sarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007. After completing various phase-II and phase-III trials demonstrating its effectiveness in treating moderate to severe ... | Magnesium gluconate is a magnesium salt of gluconate. It demonstrates the highest oral bioavailability of magnesium salts and is used as a mineral supplement. Magnesium is ubiquitous in the human body, and is naturally present in many foods, added to other food products, available as a dietary supplement and used as an... | Moderate | 1 | [
[
[
943,
24,
1473
]
],
[
[
943,
63,
544
],
[
544,
24,
1473
]
],
[
[
943,
63,
544
],
[
544,
24,
1299
],
[
1299,
24,
1473
]
],
[
[
943,
... | [
[
[
"Sarecycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium gluconate"
]
],
[
[
"Sarecycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium sulfat... | Sarecycline may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate and Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium gluconate
Sarecycline may cause a moderate interaction that could exacerbate diseases when taken w... |
DB00275 | DB06210 | 217 | 72 | [
"DDInter1330",
"DDInter631"
] | Olmesartan | Eltrombopag | Olmesartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes [telmisartan], [candesartan], [losartan], [valsartan], and [irbesartan]. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, w... | Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelet... | Moderate | 1 | [
[
[
217,
24,
72
]
],
[
[
217,
6,
15333
],
[
15333,
45,
72
]
],
[
[
217,
24,
484
],
[
484,
63,
72
]
],
[
[
217,
24,
1510
],
[
1510,
6... | [
[
[
"Olmesartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eltrombopag"
]
],
[
[
"Olmesartan",
"{u} (Compound) binds {v} (Gene)",
"SLCO1B1"
],
[
"SLCO1B1",
"{u} (Gene) is bound by {v} (Compound... | Olmesartan (Compound) binds SLCO1B1 (Gene) and SLCO1B1 (Gene) is bound by Eltrombopag (Compound)
Olmesartan may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag
Olmesartan m... |
DB00421 | DB01276 | 443 | 123 | [
"DDInter1707",
"DDInter706"
] | Spironolactone | Exenatide | Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. It promotes sodium and water excretion and potassium retention. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were disco... | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Moderate | 1 | [
[
[
443,
24,
123
]
],
[
[
443,
24,
708
],
[
708,
63,
123
]
],
[
[
443,
24,
1573
],
[
1573,
24,
123
]
],
[
[
443,
1,
303
],
[
303,
24... | [
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]... | Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Predniso... |
DB00445 | DB11652 | 322 | 1,155 | [
"DDInter655",
"DDInter1891"
] | Epirubicin | Tucatinib | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer w... | Moderate | 1 | [
[
[
322,
24,
1155
]
],
[
[
322,
63,
1101
],
[
1101,
23,
1155
]
],
[
[
322,
24,
1424
],
[
1424,
24,
1155
]
],
[
[
322,
24,
1320
],
[
1320,
... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Tucatinib
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may ... |
DB00214 | DB08912 | 1,028 | 1,040 | [
"DDInter1836",
"DDInter462"
] | Torasemide | Dabrafenib | Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993. | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
1028,
24,
1040
]
],
[
[
1028,
6,
3486
],
[
3486,
45,
1040
]
],
[
[
1028,
7,
2592
],
[
2592,
46,
1040
]
],
[
[
1028,
21,
28658
],
[
286... | [
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Torasemide",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",... | Torasemide (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Dabrafenib (Compound)
Torasemide (Compound) upregulates CEBPD (Gene) and CEBPD (Gene) is upregulated by Dabrafenib (Compound)
Torasemide (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Dabrafenib (Compound)
Torasemi... |
DB01367 | DB11837 | 1,163 | 1,297 | [
"DDInter1572",
"DDInter1351"
] | Rasagiline | Osilodrostat | Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases. | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Major | 2 | [
[
[
1163,
25,
1297
]
],
[
[
1163,
64,
222
],
[
222,
23,
1297
]
],
[
[
1163,
63,
401
],
[
401,
24,
1297
]
],
[
[
1163,
24,
659
],
[
659,
... | [
[
[
"Rasagiline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osilodrostat"
]
],
[
[
"Rasagiline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{... | Rasagiline may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Rasagiline may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may ... |
DB00524 | DB09564 | 811 | 1,296 | [
"DDInter1199",
"DDInter930"
] | Metolazone | Insulin degludec | A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss. | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
811,
24,
1296
]
],
[
[
811,
24,
1411
],
[
1411,
24,
1296
]
],
[
[
811,
63,
1645
],
[
1645,
24,
1296
]
],
[
[
811,
62,
964
],
[
964,
... | [
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
... | Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Metformin and... |
DB01142 | DB09330 | 1,264 | 985 | [
"DDInter593",
"DDInter1352"
] | Doxepin | Osimertinib | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Major | 2 | [
[
[
1264,
25,
985
]
],
[
[
1264,
62,
1247
],
[
1247,
23,
985
]
],
[
[
1264,
63,
480
],
[
480,
24,
985
]
],
[
[
1264,
24,
1033
],
[
1033,
... | [
[
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Doxepin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethox... | Doxepin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and For... |
DB01044 | DB09104 | 246 | 286 | [
"DDInter809",
"DDInter1118"
] | Gatifloxacin | Magnesium hydroxide | Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatiflox... | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Moderate | 1 | [
[
[
246,
24,
286
]
],
[
[
246,
25,
820
],
[
820,
23,
286
]
],
[
[
246,
23,
60
],
[
60,
23,
286
]
],
[
[
246,
63,
1559
],
[
1559,
23,... | [
[
[
"Gatifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alimemazine"
],
[
... | Gatifloxacin may lead to a major life threatening interaction when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Gatifloxacin may cause a minor interaction that can limit clinical effects when taken with Capecitabine and Capecita... |
DB00791 | DB01097 | 132 | 1,377 | [
"DDInter1902",
"DDInter1033"
] | Uracil mustard | Leflunomide | Nitrogen mustard derivative of uracil. It is a alkylating antineoplastic agent that is used in lymphatic malignancies, and causes mainly gastrointestinal and bone marrow damage. | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Major | 2 | [
[
[
132,
25,
1377
]
],
[
[
132,
63,
1461
],
[
1461,
23,
1377
]
],
[
[
132,
24,
949
],
[
949,
63,
1377
]
],
[
[
132,
24,
563
],
[
563,
... | [
[
[
"Uracil mustard",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Uracil mustard",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vi... | Uracil mustard may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Leflunomide
Uracil mustard may cause a moderate interaction that could exacerbate diseases when taken with Clostridium teta... |
DB00468 | DB06414 | 1,424 | 655 | [
"DDInter1557",
"DDInter703"
] | Quinine | Etravirine | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 10... | Moderate | 1 | [
[
[
1424,
24,
655
]
],
[
[
1424,
24,
786
],
[
786,
40,
655
]
],
[
[
1424,
6,
4973
],
[
4973,
45,
655
]
],
[
[
1424,
21,
28723
],
[
28723,
... | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
],
[
"... | Quinine may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine and Rilpivirine (Compound) resembles Etravirine (Compound)
Quinine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Etravirine (Compound)
Quinine (Compound) causes Malnutrition (Side Effect) and Malnutrition (S... |
DB00631 | DB01018 | 372 | 1,364 | [
"DDInter405",
"DDInter847"
] | Clofarabine | Guanfacine | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension but is now indicated as an extended release tablet for the treatment of ADHD. Guanfacine was first described in the literature in 1974. Guanfacine was granted FDA approva... | Moderate | 1 | [
[
[
372,
24,
1364
]
],
[
[
372,
63,
1512
],
[
1512,
1,
1364
]
],
[
[
372,
21,
28729
],
[
28729,
60,
1364
]
],
[
[
372,
24,
1476
],
[
1476,... | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guanfacine"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
... | Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac (Compound) resembles Guanfacine (Compound)
Clofarabine (Compound) causes Pain in extremity (Side Effect) and Pain in extremity (Side Effect) is caused by Guanfacine (Compound)
Clofarabine may cause a mo... |
DB00757 | DB09068 | 1,166 | 1,427 | [
"DDInter581",
"DDInter1948"
] | Dolasetron | Vortioxetine | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is no... | Vortioxetine is an antidepressant medication indicated for the treatment of major depressive disorder (MDD). It is classified as a serotonin modulator and stimulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin r... | Major | 2 | [
[
[
1166,
25,
1427
]
],
[
[
1166,
25,
477
],
[
477,
24,
1427
]
],
[
[
1166,
25,
971
],
[
971,
63,
1427
]
],
[
[
1166,
64,
702
],
[
702,
... | [
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vortioxetine"
]
],
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cilostazol"
],
[
"Cilostazol",
"{u}... | Dolasetron may lead to a major life threatening interaction when taken with Cilostazol and Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Dolasetron may lead to a major life threatening interaction when taken with Gilteritinib and Gilteritinib may cause a moderat... |
DB00582 | DB00586 | 1,622 | 1,512 | [
"DDInter1946",
"DDInter537"
] | Voriconazole | Diclofenac | Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increase... | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Moderate | 1 | [
[
[
1622,
24,
1512
]
],
[
[
1622,
6,
8374
],
[
8374,
45,
1512
]
],
[
[
1622,
21,
29231
],
[
29231,
60,
1512
]
],
[
[
1622,
62,
752
],
[
75... | [
[
[
"Voriconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
]
],
[
[
"Voriconazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compoun... | Voriconazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Diclofenac (Compound)
Voriconazole (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Diclofenac (Compound)
Voriconazole may cause a minor interaction that can limit clinical effects when taken with C... |
DB01281 | DB10795 | 881 | 221 | [
"DDInter5",
"DDInter1486"
] | Abatacept | Poliovirus type 1 antigen (formaldehyde inactivated) | Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1).[L20504,L42715] Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS mo... | Poliovirus type 1 antigen is a suspension of poliovirus Type 1 (Mahoney) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus Type 1. The vaccine contains purified and inactivated poliovirus type 1 that were grown from a c... | Moderate | 1 | [
[
[
881,
24,
221
]
],
[
[
881,
64,
581
],
[
581,
24,
221
]
],
[
[
881,
63,
599
],
[
599,
24,
221
]
],
[
[
881,
24,
1531
],
[
1531,
2... | [
[
[
"Abatacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Abatacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"In... | Abatacept may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Abatacept may cause a moderate interaction that could exacerbate diseases when taken w... |
DB00802 | DB11186 | 1,322 | 1,609 | [
"DDInter43",
"DDInter1427"
] | Alfentanil | Pentoxyverine | A short-acting opioid anesthetic and analgesic derivative of fentanyl. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients. | Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant , and local anesthetic properties. It is an active ingredient in over-the-counter cough suppressants in combination with guaifenesin and H1-receptor antagonists . Pentoxyverine acts on sigma... | Moderate | 1 | [
[
[
1322,
24,
1609
]
],
[
[
1322,
24,
104
],
[
104,
24,
1609
]
],
[
[
1322,
63,
999
],
[
999,
24,
1609
]
],
[
[
1322,
40,
411
],
[
411,
... | [
[
[
"Alfentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Alfentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
... | Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazi... |
DB00284 | DB09098 | 1,647 | 98 | [
"DDInter11",
"DDInter1700"
] | Acarbose | Somatrem | Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are r... | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
1647,
24,
98
]
],
[
[
1647,
63,
168
],
[
168,
23,
98
]
],
[
[
1647,
24,
1573
],
[
1573,
24,
98
]
],
[
[
1647,
23,
135
],
[
135,
... | [
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"B... | Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Somatrem
Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone may... |
DB00641 | DB11834 | 467 | 1,303 | [
"DDInter1675",
"DDInter849"
] | Simvastatin | Guselkumab | Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of _Aspergillus terreus_. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endog... | Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation . In clinical trials, guselkumab demonstra... | Moderate | 1 | [
[
[
467,
24,
1303
]
],
[
[
467,
63,
58
],
[
58,
24,
1303
]
],
[
[
467,
24,
259
],
[
259,
24,
1303
]
],
[
[
467,
74,
1463
],
[
1463,
... | [
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guselkumab"
]
],
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
],
[
... | Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Guselkumab
Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilona... |
DB00762 | DB06595 | 613 | 1,491 | [
"DDInter973",
"DDInter1214"
] | Irinotecan | Midostaurin | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cel... | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Moderate | 1 | [
[
[
613,
24,
1491
]
],
[
[
613,
63,
58
],
[
58,
24,
1491
]
],
[
[
613,
24,
1017
],
[
1017,
63,
1491
]
],
[
[
613,
23,
956
],
[
956,
... | [
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
],
[
... | Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlati... |
DB00601 | DB08889 | 453 | 350 | [
"DDInter1073",
"DDInter299"
] | Linezolid | Carfilzomib | Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the init... | Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combi... | Moderate | 1 | [
[
[
453,
24,
350
]
],
[
[
453,
21,
28762
],
[
28762,
60,
350
]
],
[
[
453,
24,
310
],
[
310,
24,
350
]
],
[
[
453,
63,
1451
],
[
1451,
... | [
[
[
"Linezolid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
]
],
[
[
"Linezolid",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused ... | Linezolid (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Carfilzomib (Compound)
Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Carfilzo... |
DB09046 | DB15035 | 1,094 | 503 | [
"DDInter1201",
"DDInter1959"
] | Metreleptin | Zanubrutinib | Metreleptin, a recombinant analog of the human hormone leptin, is an orphan drug used to treat complications of leptin deficiency in people with lipodystrophy. Lipodystrophies include a range of disorders characterized by the reduction, absence, or altered distribution of adipose tissue. Complications of lipodystrophy ... | Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long... | Moderate | 1 | [
[
[
1094,
24,
503
]
],
[
[
1094,
63,
868
],
[
868,
24,
503
]
],
[
[
1094,
24,
1320
],
[
1320,
24,
503
]
],
[
[
1094,
63,
39
],
[
39,
... | [
[
[
"Metreleptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Metreleptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
... | Metreleptin may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Metreleptin may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and El... |
DB01144 | DB11110 | 1,326 | 603 | [
"DDInter540",
"DDInter1115"
] | Diclofenamide | Magnesium citrate | A carbonic anhydrase inhibitor that is used in the treatment of glaucoma. | Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the ... | Moderate | 1 | [
[
[
1326,
24,
603
]
],
[
[
1326,
25,
57
],
[
57,
24,
603
]
],
[
[
1326,
63,
870
],
[
870,
24,
603
]
],
[
[
1326,
1,
674
],
[
674,
24... | [
[
[
"Diclofenamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Diclofenamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
... | Diclofenamide may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Fludrocorti... |
DB05528 | DB08870 | 1,070 | 850 | [
"DDInter1228",
"DDInter228"
] | Mipomersen | Brentuximab vedotin | Mipomersen sodium, which was known as the investigational drug, isis-301012, is the salt form of a synthetic phosphorothioate oligonucleotide. Mipomersen sodium prevents the formation of apo B-100, resulting in a decrease in the levels of apolipoprotein B (apo B), low density lipoprotein (LDL), and total cholesterol. M... | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Major | 2 | [
[
[
1070,
25,
850
]
],
[
[
1070,
64,
611
],
[
611,
24,
850
]
],
[
[
1070,
25,
1583
],
[
1583,
63,
850
]
],
[
[
1070,
25,
980
],
[
980,
... | [
[
[
"Mipomersen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Mipomersen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dacarbazine"
],
[
"Dacarbazine",
... | Mipomersen may lead to a major life threatening interaction when taken with Dacarbazine and Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Mipomersen may lead to a major life threatening interaction when taken with Sarilumab and Sarilumab may cause a mode... |
DB00816 | DB01261 | 1,674 | 170 | [
"DDInter1346",
"DDInter1679"
] | Orciprenaline | Sitagliptin | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improv... | Moderate | 1 | [
[
[
1674,
24,
170
]
],
[
[
1674,
21,
28921
],
[
28921,
60,
170
]
],
[
[
1674,
24,
52
],
[
52,
62,
170
]
],
[
[
1674,
24,
623
],
[
623,
... | [
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Orciprenaline",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effect) ... | Orciprenaline (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Sitagliptin (Compound)
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide and Dulaglutide may cause a minor interaction that can limit clinical effects when taken with ... |
DB00468 | DB01142 | 1,424 | 1,264 | [
"DDInter1557",
"DDInter593"
] | Quinine | Doxepin | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
1424,
24,
1264
]
],
[
[
1424,
63,
508
],
[
508,
24,
1264
]
],
[
[
1424,
24,
401
],
[
401,
24,
1264
]
],
[
[
1424,
6,
4973
],
[
4973,
... | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
[
"Proma... | Quinine may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine ma... |
DB01005 | DB08908 | 995 | 713 | [
"DDInter894",
"DDInter564"
] | Hydroxyurea | Dimethyl fumarate | Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, h... | Dimethyl fumarate is an agent indicated for the treatment of relapsing forms of multiple sclerosis.[A253942,L43752] The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MM... | Moderate | 1 | [
[
[
995,
24,
713
]
],
[
[
995,
24,
4
],
[
4,
24,
713
]
],
[
[
995,
63,
552
],
[
552,
24,
713
]
],
[
[
995,
24,
270
],
[
270,
63,
... | [
[
[
"Hydroxyurea",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
]
],
[
[
"Hydroxyurea",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesu... | Hydroxyurea may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate
Hydroxyurea may cause a moderate interaction that could exacerbate disease... |
DB00700 | DB12500 | 312 | 283 | [
"DDInter656",
"DDInter714"
] | Eplerenone | Fedratinib | Eplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. The resulting increased plasma renin activity and aldosterone c... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Major | 2 | [
[
[
312,
25,
283
]
],
[
[
312,
25,
351
],
[
351,
23,
283
]
],
[
[
312,
64,
1419
],
[
1419,
24,
283
]
],
[
[
312,
24,
885
],
[
885,
2... | [
[
[
"Eplerenone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
],
[
[
"Eplerenone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} m... | Eplerenone may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Eplerenone may lead to a major life threatening interaction when taken with Imatinib and Imatinib may cause a moderate interactio... |
DB00794 | DB06674 | 759 | 908 | [
"DDInter1521",
"DDInter837"
] | Primidone | Golimumab | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Moderate | 1 | [
[
[
759,
24,
908
]
],
[
[
759,
1,
697
],
[
697,
24,
908
]
],
[
[
759,
24,
458
],
[
458,
24,
908
]
],
[
[
759,
40,
362
],
[
362,
24,
... | [
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Golimumab"
]
],
[
[
"Primidone",
"{u} (Compound) resembles {v} (Compound)",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} may cause a mode... | Primidone (Compound) resembles Phenobarbital (Compound) and Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Primidone may cause a moderate interaction that could exacerbate diseases when taken with Tinidazole and Tinidazole may cause a moderate interaction that co... |
DB01501 | DB04844 | 1,118 | 843 | [
"DDInter549",
"DDInter1778"
] | Difenoxin | Tetrabenazine | Difenoxin is a 4-phenylpiperidine which is closely related to the opioid analgesic meperidine. Difenoxin alone is a USA Schedule I controlled drug, as it may be habit forming. However, it is listed as a Schedule IV controlled drug if combined with atropine, which is added to decrease deliberate misuse. Motofen(R) is a ... | A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008. | Moderate | 1 | [
[
[
1118,
24,
843
]
],
[
[
1118,
24,
649
],
[
649,
24,
843
]
],
[
[
1118,
63,
1242
],
[
1242,
24,
843
]
],
[
[
1118,
40,
543
],
[
543,
... | [
[
[
"Difenoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetrabenazine"
]
],
[
[
"Difenoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
... | Difenoxin may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Tetrabenazine
Difenoxin may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetir... |
DB00361 | DB06414 | 134 | 655 | [
"DDInter1939",
"DDInter703"
] | Vinorelbine | Etravirine | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-g... | Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 10... | Moderate | 1 | [
[
[
134,
24,
655
]
],
[
[
134,
6,
4973
],
[
4973,
45,
655
]
],
[
[
134,
21,
28723
],
[
28723,
60,
655
]
],
[
[
134,
63,
1101
],
[
1101,
... | [
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
]
],
[
[
"Vinorelbine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",... | Vinorelbine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Etravirine (Compound)
Vinorelbine (Compound) causes Malnutrition (Side Effect) and Malnutrition (Side Effect) is caused by Etravirine (Compound)
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene a... |
DB00087 | DB01005 | 599 | 995 | [
"DDInter41",
"DDInter894"
] | Alemtuzumab | Hydroxyurea | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, h... | Moderate | 1 | [
[
[
599,
24,
995
]
],
[
[
599,
24,
1660
],
[
1660,
40,
995
]
],
[
[
599,
24,
1238
],
[
1238,
24,
995
]
],
[
[
599,
24,
869
],
[
869,
... | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyurea"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetohydroxamic acid"
... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Acetohydroxamic acid and Acetohydroxamic acid (Compound) resembles Hydroxyurea (Compound)
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Pentostatin and Pentostatin may cause a modera... |
DB00518 | DB00872 | 510 | 1,080 | [
"DDInter35",
"DDInter438"
] | Albendazole | Conivaptan | A benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38) | Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). | Moderate | 1 | [
[
[
510,
24,
1080
]
],
[
[
510,
6,
8374
],
[
8374,
45,
1080
]
],
[
[
510,
21,
28646
],
[
28646,
60,
1080
]
],
[
[
510,
63,
1101
],
[
1101,... | [
[
[
"Albendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Conivaptan"
]
],
[
[
"Albendazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)... | Albendazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Conivaptan (Compound)
Albendazole (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Conivaptan (Compound)
Albendazole may cause ... |
DB04932 | DB14357 | 1,564 | 944 | [
"DDInter491",
"DDInter347"
] | Defibrotide | Chamomile | Defibrotide is the sodium salt of a mixture of single-stranded oligodeoxyribonucleotides derived from porcine mucosal DNA. It has been shown to have antithrombotic, anti-inflammatory and anti-ischemic properties (but without associated significant systemic anticoagulant effects). It is marketed under the brand names Da... | Chamomile is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug. | Minor | 0 | [
[
[
1564,
23,
944
]
],
[
[
1564,
25,
256
],
[
256,
23,
944
]
],
[
[
1564,
64,
582
],
[
582,
23,
944
]
],
[
[
1564,
63,
1061
],
[
1061,
... | [
[
[
"Defibrotide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
]
],
[
[
"Defibrotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prasugrel"
],
[
"Prasugrel",
... | Defibrotide may lead to a major life threatening interaction when taken with Prasugrel and Prasugrel may cause a minor interaction that can limit clinical effects when taken with Chamomile
Defibrotide may lead to a major life threatening interaction when taken with Reteplase and Reteplase may cause a minor interaction ... |
DB00308 | DB11110 | 347 | 603 | [
"DDInter901",
"DDInter1115"
] | Ibutilide | Magnesium citrate | Ibutilide is a Class III antiarrhythmic agent available in intravenous formulations. It is indicated for the conversion of acute atrial flutter and recent onset atrial fibrillation to normal sinus rhythm (NSR). | Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the ... | Moderate | 1 | [
[
[
347,
24,
603
]
],
[
[
347,
25,
57
],
[
57,
24,
603
]
],
[
[
347,
25,
484
],
[
484,
63,
603
]
],
[
[
347,
40,
17
],
[
17,
24,
... | [
[
[
"Ibutilide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Ibutilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
[
... | Ibutilide may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Ibutilide may lead to a major life threatening interaction when taken with Entrectinib and Entrectinib may ca... |
DB00599 | DB01069 | 682 | 401 | [
"DDInter1795",
"DDInter1533"
] | Thiopental | Promethazine | A barbiturate that is administered intravenously for the induction of general anesthesia or for the production of complete anesthesia of short duration. It is also used for hypnosis and for the control of convulsive states. It has been used in neurosurgical patients to reduce increased intracranial pressure. It does no... | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Minor | 0 | [
[
[
682,
23,
401
]
],
[
[
682,
24,
1264
],
[
1264,
63,
401
]
],
[
[
682,
63,
701
],
[
701,
24,
401
]
],
[
[
682,
24,
770
],
[
770,
2... | [
[
[
"Thiopental",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Promethazine"
]
],
[
[
"Thiopental",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
... | Thiopental may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Thiopental may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine... |
DB00334 | DB01276 | 867 | 123 | [
"DDInter1326",
"DDInter706"
] | Olanzapine | Exenatide | Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug inte... | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Moderate | 1 | [
[
[
867,
24,
123
]
],
[
[
867,
24,
820
],
[
820,
24,
123
]
],
[
[
867,
63,
1685
],
[
1685,
24,
123
]
],
[
[
867,
24,
1154
],
[
1154,
... | [
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
... | Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Insulin human and In... |
DB00514 | DB11186 | 506 | 1,609 | [
"DDInter527",
"DDInter1427"
] | Dextromethorphan | Pentoxyverine | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant , and local anesthetic properties. It is an active ingredient in over-the-counter cough suppressants in combination with guaifenesin and H1-receptor antagonists . Pentoxyverine acts on sigma... | Moderate | 1 | [
[
[
506,
24,
1609
]
],
[
[
506,
24,
314
],
[
314,
24,
1609
]
],
[
[
506,
63,
556
],
[
556,
24,
1609
]
],
[
[
506,
64,
758
],
[
758,
... | [
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nalbuphine"
... | Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Nalbuphine and Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Valpro... |
DB00046 | DB00373 | 1,179 | 461 | [
"DDInter940",
"DDInter1809"
] | Insulin lispro | Timolol | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective ag... | Moderate | 1 | [
[
[
1179,
24,
461
]
],
[
[
1179,
24,
729
],
[
729,
40,
461
]
],
[
[
1179,
24,
1479
],
[
1479,
62,
461
]
],
[
[
1179,
24,
1152
],
[
1152,
... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Penbutolol"
],
... | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Penbutolol and Penbutolol (Compound) resembles Timolol (Compound)
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a minor ... |
DB01041 | DB09351 | 770 | 722 | [
"DDInter1789",
"DDInter1048"
] | Thalidomide | Levobetaxolol (ophthalmic) | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | (S)-betaxolol is the (S)-enantiomer of betaxolol. It is an enantiomer of a (R)-betaxolol. | Moderate | 1 | [
[
[
770,
24,
722
]
],
[
[
770,
24,
1276
],
[
1276,
63,
722
]
],
[
[
770,
24,
1593
],
[
1593,
24,
722
]
],
[
[
770,
25,
1053
],
[
1053,
... | [
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levobetaxolol"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alectinib"
],
... | Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Levobetaxolol
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Alectinib and Alectinib may cause a moderate interaction that could exacerbate diseases when taken with Levobetaxolol
Thal... |
DB00275 | DB00712 | 217 | 1,274 | [
"DDInter1330",
"DDInter763"
] | Olmesartan | Flurbiprofen | Olmesartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes [telmisartan], [candesartan], [losartan], [valsartan], and [irbesartan]. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, w... | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically p... | Moderate | 1 | [
[
[
217,
24,
1274
]
],
[
[
217,
21,
28769
],
[
28769,
60,
1274
]
],
[
[
217,
1,
240
],
[
240,
24,
1274
]
],
[
[
217,
24,
175
],
[
175,
... | [
[
[
"Olmesartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
]
],
[
[
"Olmesartan",
"{u} (Compound) causes {v} (Side Effect)",
"Feeling abnormal"
],
[
"Feeling abnormal",
"{u} (Side... | Olmesartan (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Flurbiprofen (Compound)
Olmesartan (Compound) resembles Losartan (Compound) and Losartan may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen
Olmesartan may cause a moderat... |
DB05773 | DB06700 | 1,047 | 643 | [
"DDInter1848",
"DDInter511"
] | Trastuzumab emtansine | Desvenlafaxine | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-mic... | Desvenlafaxine (O-desmethylvenlafaxine) is the 0-demetyhlated active metabolite of [venlafaxine]. Like its parent drug, desvenlafaxine is also an antidepressant belonging to the class of serotonin-norepinephrine reuptake inhibitor (SNRI) class.[A261266,A261266] It was approved by the FDA in 2008 for the treatment of ad... | Moderate | 1 | [
[
[
1047,
24,
643
]
],
[
[
1047,
63,
1100
],
[
1100,
1,
643
]
],
[
[
1047,
25,
292
],
[
292,
63,
643
]
],
[
[
1047,
63,
1274
],
[
1274,
... | [
[
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
]
],
[
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"V... | Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine (Compound) resembles Desvenlafaxine (Compound)
Trastuzumab emtansine may lead to a major life threatening interaction when taken with Regorafenib and Regorafenib may cause a moderate interac... |
DB01101 | DB01377 | 60 | 1,283 | [
"DDInter285",
"DDInter1119"
] | Capecitabine | Magnesium oxide | Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. | Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. | Minor | 0 | [
[
[
60,
23,
1283
]
],
[
[
60,
23,
255
],
[
255,
63,
1283
]
],
[
[
60,
62,
246
],
[
246,
24,
1283
]
],
[
[
60,
23,
945
],
[
945,
24,
... | [
[
[
"Capecitabine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium oxide"
]
],
[
[
"Capecitabine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Delafloxacin"
],
... | Capecitabine may cause a minor interaction that can limit clinical effects when taken with Delafloxacin and Delafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide
Capecitabine may cause a minor interaction that can limit clinical effects when taken with Gatifloxacin... |
DB01001 | DB01254 | 688 | 1,213 | [
"DDInter1632",
"DDInter484"
] | Salbutamol | Dasatinib | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Moderate | 1 | [
[
[
688,
24,
1213
]
],
[
[
688,
6,
8374
],
[
8374,
45,
1213
]
],
[
[
688,
6,
3576
],
[
3576,
57,
1213
]
],
[
[
688,
21,
28882
],
[
28882,
... | [
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
],
[
[
"Salbutamol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Salbutamol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dasatinib (Compound)
Salbutamol (Compound) binds ADRB2 (Gene) and ADRB2 (Gene) is downregulated by Dasatinib (Compound)
Salbutamol (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by ... |
DB00218 | DB08875 | 1,176 | 1,618 | [
"DDInter1247",
"DDInter262"
] | Moxifloxacin | Cabozantinib | Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment. | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Major | 2 | [
[
[
1176,
25,
1618
]
],
[
[
1176,
23,
112
],
[
112,
23,
1618
]
],
[
[
1176,
24,
384
],
[
384,
63,
1618
]
],
[
[
1176,
24,
480
],
[
480,
... | [
[
[
"Moxifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Moxifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Met... | Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib an... |
DB00307 | DB00564 | 1,101 | 1,236 | [
"DDInter202",
"DDInter293"
] | Bexarotene | Carbamazepine | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbam... | Minor | 0 | [
[
[
1101,
23,
1236
]
],
[
[
1101,
24,
307
],
[
307,
1,
1236
]
],
[
[
1101,
62,
362
],
[
362,
1,
1236
]
],
[
[
1101,
23,
1335
],
[
1335,
... | [
[
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Carbamazepine"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Modafinil"
],
[
... | Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil (Compound) resembles Carbamazepine (Compound)
Bexarotene may cause a minor interaction that can limit clinical effects when taken with Phenytoin and Phenytoin (Compound) resembles Carbamazepine (Compound)
... |
DB01174 | DB06168 | 697 | 1,531 | [
"DDInter1442",
"DDInter281"
] | Phenobarbital | Canakinumab | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | Moderate | 1 | [
[
[
697,
24,
1531
]
],
[
[
697,
25,
1362
],
[
1362,
63,
1531
]
],
[
[
697,
25,
1213
],
[
1213,
24,
1531
]
],
[
[
697,
63,
1031
],
[
1031,
... | [
[
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
]
],
[
[
"Phenobarbital",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
],
[
"Olapa... | Phenobarbital may lead to a major life threatening interaction when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Phenobarbital may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate int... |
DB00631 | DB12240 | 372 | 110 | [
"DDInter405",
"DDInter1485"
] | Clofarabine | Polatuzumab vedotin | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable link... | Moderate | 1 | [
[
[
372,
24,
110
]
],
[
[
372,
24,
467
],
[
467,
24,
110
]
],
[
[
372,
63,
1419
],
[
1419,
24,
110
]
],
[
[
372,
25,
770
],
[
770,
2... | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polatuzumab vedotin"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
... | Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab vedotin
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib... |
DB01105 | DB01175 | 222 | 318 | [
"DDInter1665",
"DDInter672"
] | Sibutramine | Escitalopram | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible ... | Major | 2 | [
[
[
222,
25,
318
]
],
[
[
222,
64,
1230
],
[
1230,
1,
318
]
],
[
[
222,
6,
8374
],
[
8374,
45,
318
]
],
[
[
222,
54,
19229
],
[
19229,
... | [
[
[
"Sibutramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Escitalopram"
]
],
[
[
"Sibutramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Citalopram"
],
[
"Citalopram",
"{... | Sibutramine may lead to a major life threatening interaction when taken with Citalopram and Citalopram (Compound) resembles Escitalopram (Compound)
Sibutramine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Escitalopram (Compound)
Sibutramine (Compound) is included by Serotonin Uptake Inhibitors (Pharmaco... |
DB00860 | DB00872 | 891 | 1,080 | [
"DDInter1513",
"DDInter438"
] | Prednisolone | Conivaptan | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). | Moderate | 1 | [
[
[
891,
24,
1080
]
],
[
[
891,
6,
8374
],
[
8374,
45,
1080
]
],
[
[
891,
21,
28769
],
[
28769,
60,
1080
]
],
[
[
891,
63,
126
],
[
126,
... | [
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Conivaptan"
]
],
[
[
"Prednisolone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compoun... | Prednisolone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Conivaptan (Compound)
Prednisolone (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Conivaptan (Compound)
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with... |
DB00762 | DB04855 | 613 | 540 | [
"DDInter973",
"DDInter602"
] | Irinotecan | Dronedarone | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cel... | Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate contro... | Moderate | 1 | [
[
[
613,
24,
540
]
],
[
[
613,
24,
33
],
[
33,
40,
540
]
],
[
[
613,
6,
8374
],
[
8374,
45,
540
]
],
[
[
613,
21,
29113
],
[
29113,
... | [
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronedarone"
]
],
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiodarone"
],
[
... | Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Amiodarone and Amiodarone (Compound) resembles Dronedarone (Compound)
Irinotecan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dronedarone (Compound)
Irinotecan (Compound) causes Hypokalaemia (Side Effect) and Hypo... |
DB00682 | DB11652 | 126 | 1,155 | [
"DDInter1951",
"DDInter1891"
] | Warfarin | Tucatinib | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer w... | Moderate | 1 | [
[
[
126,
24,
1155
]
],
[
[
126,
24,
222
],
[
222,
23,
1155
]
],
[
[
126,
63,
1424
],
[
1424,
24,
1155
]
],
[
[
126,
25,
609
],
[
609,
... | [
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Tucatinib
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may ca... |
DB00647 | DB00927 | 675 | 1,559 | [
"DDInter528",
"DDInter712"
] | Dextropropoxyphene | Famotidine | Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the mar... | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | Moderate | 1 | [
[
[
675,
24,
1559
]
],
[
[
675,
18,
4930
],
[
4930,
57,
1559
]
],
[
[
675,
21,
28826
],
[
28826,
60,
1559
]
],
[
[
675,
24,
286
],
[
286,
... | [
[
[
"Dextropropoxyphene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
]
],
[
[
"Dextropropoxyphene",
"{u} (Compound) downregulates {v} (Gene)",
"DLD"
],
[
"DLD",
"{u} (Gene) is downreg... | Dextropropoxyphene (Compound) downregulates DLD (Gene) and DLD (Gene) is downregulated by Famotidine (Compound)
Dextropropoxyphene (Compound) causes Jaundice (Side Effect) and Jaundice (Side Effect) is caused by Famotidine (Compound)
Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases whe... |
DB00586 | DB00912 | 1,512 | 473 | [
"DDInter537",
"DDInter1581"
] | Diclofenac | Repaglinide | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Moderate | 1 | [
[
[
1512,
24,
473
]
],
[
[
1512,
6,
1829
],
[
1829,
45,
473
]
],
[
[
1512,
21,
28873
],
[
28873,
60,
473
]
],
[
[
1512,
24,
1026
],
[
1026... | [
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
]
],
[
[
"Diclofenac",
"{u} (Compound) binds {v} (Gene)",
"ALB"
],
[
"ALB",
"{u} (Gene) is bound by {v} (Compound)",
... | Diclofenac (Compound) binds ALB (Gene) and ALB (Gene) is bound by Repaglinide (Compound)
Diclofenac (Compound) causes Pancreatitis (Side Effect) and Pancreatitis (Side Effect) is caused by Repaglinide (Compound)
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Oxandrolone and O... |
DB04953 | DB06176 | 495 | 1,342 | [
"DDInter708",
"DDInter1616"
] | Ezogabine | Romidepsin | Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients wi... | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Moderate | 1 | [
[
[
495,
24,
1342
]
],
[
[
495,
62,
112
],
[
112,
23,
1342
]
],
[
[
495,
63,
485
],
[
485,
24,
1342
]
],
[
[
495,
24,
1616
],
[
1616,
... | [
[
[
"Ezogabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Ezogabine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Ezogabine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Romidepsin
Ezogabine may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Penta... |
DB01254 | DB11979 | 1,213 | 1,320 | [
"DDInter484",
"DDInter625"
] | Dasatinib | Elagolix | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
1213,
24,
1320
]
],
[
[
1213,
63,
608
],
[
608,
23,
1320
]
],
[
[
1213,
23,
271
],
[
271,
23,
1320
]
],
[
[
1213,
24,
1612
],
[
1612,
... | [
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
"... | Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Elagolix
Dasatinib may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron may c... |
DB00495 | DB06176 | 139 | 1,342 | [
"DDInter1961",
"DDInter1616"
] | Zidovudine | Romidepsin | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain... | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Moderate | 1 | [
[
[
139,
24,
1342
]
],
[
[
139,
24,
485
],
[
485,
24,
1342
]
],
[
[
139,
24,
1619
],
[
1619,
63,
1342
]
],
[
[
139,
63,
66
],
[
66,
... | [
[
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
],
[
... | Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucap... |
DB00280 | DB01087 | 494 | 1,520 | [
"DDInter575",
"DDInter1520"
] | Disopyramide | Primaquine | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Ad... | Major | 2 | [
[
[
494,
25,
1520
]
],
[
[
494,
25,
1487
],
[
1487,
64,
1520
]
],
[
[
494,
6,
8374
],
[
8374,
45,
1520
]
],
[
[
494,
21,
28722
],
[
28722,... | [
[
[
"Disopyramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Primaquine"
]
],
[
[
"Disopyramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydroxychloro... | Disopyramide may lead to a major life threatening interaction when taken with Hydroxychloroquine and Hydroxychloroquine may lead to a major life threatening interaction when taken with Primaquine
Disopyramide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Primaquine (Compound)
Disopyramide (Compound) caus... |
DB00563 | DB01165 | 663 | 1,539 | [
"DDInter1174",
"DDInter1325"
] | Methotrexate | Ofloxacin | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. | Moderate | 1 | [
[
[
663,
24,
1539
]
],
[
[
663,
63,
1467
],
[
1467,
1,
1539
]
],
[
[
663,
24,
945
],
[
945,
40,
1539
]
],
[
[
663,
24,
739
],
[
739,
... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ofloxacin"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enoxacin"
],
[
... | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Enoxacin and Enoxacin (Compound) resembles Ofloxacin (Compound)
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Ofloxacin (Compound... |
DB00620 | DB00960 | 175 | 887 | [
"DDInter1855",
"DDInter1471"
] | Triamcinolone | Pindolol | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension. Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia. Research into pindolol's use in the treatment of hypertension began in the earl... | Moderate | 1 | [
[
[
175,
24,
887
]
],
[
[
175,
24,
819
],
[
819,
40,
887
]
],
[
[
175,
23,
1148
],
[
1148,
63,
887
]
],
[
[
175,
63,
88
],
[
88,
40,... | [
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pindolol"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acebutolol"
],
... | Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Acebutolol and Acebutolol (Compound) resembles Pindolol (Compound)
Triamcinolone may cause a minor interaction that can limit clinical effects when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that... |
DB00850 | DB08824 | 1,630 | 591 | [
"DDInter1432",
"DDInter959"
] | Perphenazine | Ioflupane I-123 | An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. | Ioflupane (I-123) is a radiopharmaceutical used to image dopamine neurons and diagnose Parkinsonian syndromes. | Moderate | 1 | [
[
[
1630,
24,
591
]
],
[
[
1630,
21,
28762
],
[
28762,
60,
591
]
],
[
[
1630,
1,
684
],
[
684,
24,
591
]
],
[
[
1630,
35,
401
],
[
401,
... | [
[
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioflupane I-123"
]
],
[
[
"Perphenazine",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) ... | Perphenazine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ioflupane I-123 (Compound)
Perphenazine (Compound) resembles Thioridazine (Compound) and Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Ioflupane I-123
Perphenazine (Compound) rese... |
DB00570 | DB01320 | 147 | 651 | [
"DDInter1936",
"DDInter783"
] | Vinblastine | Fosphenytoin | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Moderate | 1 | [
[
[
147,
24,
651
]
],
[
[
147,
23,
307
],
[
307,
1,
651
]
],
[
[
147,
63,
362
],
[
362,
1,
651
]
],
[
[
147,
6,
8374
],
[
8374,
45,
... | [
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Vinblastine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
... | Vinblastine may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil (Compound) resembles Fosphenytoin (Compound)
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Fosphenytoin (Compound)
... |
DB00501 | DB00996 | 752 | 1,198 | [
"DDInter380",
"DDInter791"
] | Cimetidine | Gabapentin | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Gabapentin is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid ([GABA]) that was first approved for use in the United States in 1993. It was originally developed as a novel anti-epileptic for the treatment of certain types of seizures[A186277,A186143] - today it is also widely used to tr... | Minor | 0 | [
[
[
752,
23,
1198
]
],
[
[
752,
21,
29648
],
[
29648,
60,
1198
]
],
[
[
752,
23,
1384
],
[
1384,
62,
1198
]
],
[
[
752,
24,
1487
],
[
1487... | [
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gabapentin"
]
],
[
[
"Cimetidine",
"{u} (Compound) causes {v} (Side Effect)",
"Disorientation"
],
[
"Disorientation",
"{u} (Side Effect)... | Cimetidine (Compound) causes Disorientation (Side Effect) and Disorientation (Side Effect) is caused by Gabapentin (Compound)
Cimetidine may cause a minor interaction that can limit clinical effects when taken with Magaldrate and Magaldrate may cause a minor interaction that can limit clinical effects when taken with G... |
DB00734 | DB01284 | 1,664 | 1,042 | [
"DDInter1605",
"DDInter1782"
] | Risperidone | Tetracosactide | Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. ... | Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticoste... | Moderate | 1 | [
[
[
1664,
24,
1042
]
],
[
[
1664,
24,
455
],
[
455,
23,
1042
]
],
[
[
1664,
24,
659
],
[
659,
62,
1042
]
],
[
[
1664,
24,
761
],
[
761,
... | [
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
... | Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a minor interaction that can limit clinical effects when taken with Tetracosactide
Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vi... |
DB00741 | DB09293 | 167 | 116 | [
"DDInter885",
"DDInter954"
] | Hydrocortisone | Iodide I-131 | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Iodide I-131 (as Sodium iodide I-131) is a radioisotopic drug used for the treatment and palliation of thyroid malignancy. Iodine-131 is notable for causing mutation and death in cells that it penetrates, which is due to its mode of beta decay. As a result of beta decay, approximately 10% of its energy and radiation do... | Moderate | 1 | [
[
[
167,
24,
116
]
],
[
[
167,
1,
1486
],
[
1486,
24,
116
]
],
[
[
167,
24,
1004
],
[
1004,
63,
116
]
],
[
[
167,
63,
126
],
[
126,
... | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-131"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Methylprednisolone"
],
[
"Methylprednisolone",
... | Hydrocortisone (Compound) resembles Methylprednisolone (Compound) and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Phenyl salicylate and Phenyl salicylate may... |
DB00176 | DB00261 | 529 | 702 | [
"DDInter770",
"DDInter93"
] | Fluvoxamine | Anagrelide | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Moderate | 1 | [
[
[
529,
24,
702
]
],
[
[
529,
6,
7950
],
[
7950,
45,
702
]
],
[
[
529,
21,
29549
],
[
29549,
60,
702
]
],
[
[
529,
24,
263
],
[
263,
... | [
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anagrelide"
]
],
[
[
"Fluvoxamine",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)... | Fluvoxamine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Anagrelide (Compound)
Fluvoxamine (Compound) causes Osteoarthritis (Side Effect) and Osteoarthritis (Side Effect) is caused by Anagrelide (Compound)
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Axitin... |
DB06822 | DB08896 | 802 | 292 | [
"DDInter1812",
"DDInter1576"
] | Tinzaparin | Regorafenib | Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. Tinzaparin is composed of molecules with and without a special site for h... | Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in Ap... | Major | 2 | [
[
[
802,
25,
292
]
],
[
[
802,
63,
643
],
[
643,
24,
292
]
],
[
[
802,
24,
637
],
[
637,
24,
292
]
],
[
[
802,
24,
41
],
[
41,
63,
... | [
[
[
"Tinzaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Regorafenib"
]
],
[
[
"Tinzaparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
],
[
"Desve... | Tinzaparin may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine and Desvenlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib
Tinzaparin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase... |
DB01030 | DB14444 | 869 | 151 | [
"DDInter1835",
"DDInter924"
] | Topotecan | Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. | A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immuno... | Moderate | 1 | [
[
[
869,
24,
151
]
],
[
[
869,
63,
66
],
[
66,
24,
151
]
],
[
[
869,
24,
1619
],
[
1619,
24,
151
]
],
[
[
869,
25,
375
],
[
375,
24,... | [
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
],
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exa... | Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Topotecan may cause a moderate interac... |
DB00352 | DB05015 | 482 | 1,077 | [
"DDInter1814",
"DDInter174"
] | Tioguanine | Belinostat | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with... | Moderate | 1 | [
[
[
482,
24,
1077
]
],
[
[
482,
63,
1253
],
[
1253,
24,
1077
]
],
[
[
482,
24,
1136
],
[
1136,
63,
1077
]
],
[
[
482,
24,
869
],
[
869,
... | [
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belinostat"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palifermin"
],
[
... | Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Palifermin and Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Belinostat
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Denosumab and Denosum... |
DB00679 | DB11110 | 684 | 603 | [
"DDInter1796",
"DDInter1115"
] | Thioridazine | Magnesium citrate | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazi... | Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the ... | Moderate | 1 | [
[
[
684,
24,
603
]
],
[
[
684,
25,
57
],
[
57,
24,
603
]
],
[
[
684,
40,
9
],
[
9,
24,
603
]
],
[
[
684,
24,
870
],
[
870,
24,
... | [
[
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Thioridazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
[
... | Thioridazine may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Thioridazine (Compound) resembles Methotrimeprazine (Compound) and Methotrimeprazine may cause a moderate ... |
DB00358 | DB01166 | 1,010 | 477 | [
"DDInter1140",
"DDInter379"
] | Mefloquine | Cilostazol | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortali... | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Moderate | 1 | [
[
[
1010,
24,
477
]
],
[
[
1010,
6,
8374
],
[
8374,
45,
477
]
],
[
[
1010,
18,
2201
],
[
2201,
57,
477
]
],
[
[
1010,
21,
29340
],
[
29340... | [
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Mefloquine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Mefloquine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cilostazol (Compound)
Mefloquine (Compound) downregulates PPP2R5E (Gene) and PPP2R5E (Gene) is downregulated by Cilostazol (Compound)
Mefloquine (Compound) causes Stevens-Johnson syndrome (Side Effect) and Stevens-Johnson syndrome (Side Effect) is ... |
DB00701 | DB09074 | 1,091 | 1,362 | [
"DDInter90",
"DDInter1327"
] | Amprenavir | Olaparib | Amprenavir is a protease inhibitor used to treat HIV infection. | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Major | 2 | [
[
[
1091,
25,
1362
]
],
[
[
1091,
24,
2
],
[
2,
24,
1362
]
],
[
[
1091,
25,
1478
],
[
1478,
24,
1362
]
],
[
[
1091,
63,
353
],
[
353,
... | [
[
[
"Amprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
]
],
[
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alosetron"
],
[
"Alosetron",
... | Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Alosetron and Alosetron may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Amprenavir may lead to a major life threatening interaction when taken with Ivacaftor and Ivacaftor may cause a mode... |
DB00220 | DB00673 | 798 | 723 | [
"DDInter1276",
"DDInter112"
] | Nelfinavir | Aprepitant | Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Moderate | 1 | [
[
[
798,
24,
723
]
],
[
[
798,
6,
7950
],
[
7950,
45,
723
]
],
[
[
798,
21,
28847
],
[
28847,
60,
723
]
],
[
[
798,
23,
222
],
[
222,
... | [
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
]
],
[
[
"Nelfinavir",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",... | Nelfinavir (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Aprepitant (Compound)
Nelfinavir (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Aprepitant (Compound)
Nelfinavir may cause a minor interaction that can limit clinical effects when taken with Sibutramine and... |
DB09054 | DB11732 | 384 | 1,097 | [
"DDInter905",
"DDInter1027"
] | Idelalisib | Lasmiditan | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Lasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019.[L9338,L9356] It was also approved by the European Commission on August 17, 2022. Traditionally, the triptan class of anti-migraine medications (e.g. [sumatriptan]) have se... | Moderate | 1 | [
[
[
384,
24,
1097
]
],
[
[
384,
63,
1181
],
[
1181,
24,
1097
]
],
[
[
384,
25,
971
],
[
971,
63,
1097
]
],
[
[
384,
64,
478
],
[
478,
... | [
[
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lasmiditan"
]
],
[
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terfenadine"
],
[
... | Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Idelalisib may lead to a major life threatening interaction when taken with Gilteritinib and Gilteritinib may ... |
DB01165 | DB09154 | 1,539 | 1,475 | [
"DDInter1325",
"DDInter1686"
] | Ofloxacin | Sodium citrate | A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. | Sodium citrate is the sodium salt of citric acid. It is white, crystalline powder or white, granular crystals, slightly deliquescent in moist air, freely soluble in water, practically insoluble in alcohol. Like citric acid, it has a sour taste. From the medical point of view, it is used as alkalinizing agent. It works ... | Moderate | 1 | [
[
[
1539,
24,
1475
]
],
[
[
1539,
63,
355
],
[
355,
23,
1475
]
],
[
[
1539,
64,
1411
],
[
1411,
23,
1475
]
],
[
[
1539,
40,
1467
],
[
1467... | [
[
[
"Ofloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium citrate"
]
],
[
[
"Ofloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
],
[
... | Ofloxacin may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a minor interaction that can limit clinical effects when taken with Sodium citrate
Ofloxacin may lead to a major life threatening interaction when taken with Tolbutamide and Tolbutamide may cause ... |
DB06186 | DB09061 | 1,439 | 1,627 | [
"DDInter969",
"DDInter284"
] | Ipilimumab | Cannabidiol | Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex. Ipilimumab was granted FDA approva... | Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact medical i... | Moderate | 1 | [
[
[
1439,
24,
1627
]
],
[
[
1439,
24,
384
],
[
384,
23,
1627
]
],
[
[
1439,
63,
597
],
[
597,
23,
1627
]
],
[
[
1439,
63,
467
],
[
467,
... | [
[
[
"Ipilimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
]
],
[
[
"Ipilimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
... | Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a minor interaction that can limit clinical effects when taken with Cannabidiol
Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Ch... |
DB00862 | DB01240 | 1,005 | 885 | [
"DDInter1918",
"DDInter657"
] | Vardenafil | Epoprostenol | Vardenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) and an oral therapy for the treatment of erectile dysfunction.[L45563,L45568] During sexual stimulation, nitric oxide (NO) is released from nerve endings and endothelial cells in the corpus cavernosum, ... | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Moderate | 1 | [
[
[
1005,
24,
885
]
],
[
[
1005,
63,
1061
],
[
1061,
1,
885
]
],
[
[
1005,
21,
28684
],
[
28684,
60,
885
]
],
[
[
1005,
24,
1450
],
[
1450... | [
[
[
"Vardenafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
],
[
[
"Vardenafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
... | Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) resembles Epoprostenol (Compound)
Vardenafil (Compound) causes Hypoaesthesia (Side Effect) and Hypoaesthesia (Side Effect) is caused by Epoprostenol (Compound)
Vardenafil may cause a moder... |
DB00193 | DB11718 | 534 | 927 | [
"DDInter1841",
"DDInter640"
] | Tramadol | Encorafenib | Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatmen... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
534,
24,
927
]
],
[
[
534,
23,
112
],
[
112,
23,
927
]
],
[
[
534,
24,
720
],
[
720,
24,
927
]
],
[
[
534,
25,
1264
],
[
1264,
2... | [
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Tramadol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Tramadol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil and Minera... |
DB00446 | DB00911 | 597 | 458 | [
"DDInter351",
"DDInter1811"
] | Chloramphenicol | Tinidazole | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | A nitroimidazole antitrichomonal agent effective against _Trichomonas vaginalis_, _Entamoeba histolytica_, and _Giardia lamblia_ infections. | Moderate | 1 | [
[
[
597,
24,
458
]
],
[
[
597,
24,
112
],
[
112,
1,
458
]
],
[
[
597,
6,
8374
],
[
8374,
45,
458
]
],
[
[
597,
21,
28882
],
[
28882,
... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tinidazole"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
... | Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole (Compound) resembles Tinidazole (Compound)
Chloramphenicol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Tinidazole (Compound)
Chloramphenicol (Compound) causes Body temperature... |
DB00220 | DB01177 | 798 | 77 | [
"DDInter1276",
"DDInter904"
] | Nelfinavir | Idarubicin | Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Moderate | 1 | [
[
[
798,
24,
77
]
],
[
[
798,
6,
6017
],
[
6017,
45,
77
]
],
[
[
798,
7,
6952
],
[
6952,
46,
77
]
],
[
[
798,
7,
5178
],
[
5178,
57,... | [
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
]
],
[
[
"Nelfinavir",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",... | Nelfinavir (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Idarubicin (Compound)
Nelfinavir (Compound) upregulates MCOLN1 (Gene) and MCOLN1 (Gene) is upregulated by Idarubicin (Compound)
Nelfinavir (Compound) upregulates XBP1 (Gene) and XBP1 (Gene) is downregulated by Idarubicin (Compound)
Nelfinavir (Comp... |
DB00446 | DB12834 | 597 | 148 | [
"DDInter351",
"DDInter1649"
] | Chloramphenicol | Secnidazole | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Secnidazole is a second-generation 5-nitroimidazole antimicrobial agent. It is structurally related to other 5-nitroimidazoles, including and , but displays improved oral absorption and a longer terminal elimination half-life than other drugs in this class. Secnidazole is selective against many anaerobic Gram-positive ... | Moderate | 1 | [
[
[
597,
24,
148
]
],
[
[
597,
24,
1593
],
[
1593,
24,
148
]
],
[
[
597,
63,
491
],
[
491,
24,
148
]
],
[
[
597,
24,
1330
],
[
1330,
... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secnidazole"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
... | Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Peginterfe... |
DB09054 | DB12001 | 384 | 564 | [
"DDInter905",
"DDInter7"
] | Idelalisib | Abemaciclib | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the trea... | Major | 2 | [
[
[
384,
25,
564
]
],
[
[
384,
63,
536
],
[
536,
24,
564
]
],
[
[
384,
24,
748
],
[
748,
24,
564
]
],
[
[
384,
64,
392
],
[
392,
24,... | [
[
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abemaciclib"
]
],
[
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secobarbital"
],
[
"Secobar... | Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital and Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib
Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine ... |
DB00877 | DB14711 | 629 | 779 | [
"DDInter1678",
"DDInter1680"
] | Sirolimus | Smallpox (Vaccinia) Vaccine, Live | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | The New York City Board of Health strain of _Vaccinia_ is a viral strain used as a component of some smallpox vaccinations. ACAM2000, a percutaneously administered smallpox vaccine that was approved by the FDA in 2007, contains live antigens of this strain. | Major | 2 | [
[
[
629,
25,
779
]
],
[
[
629,
64,
1064
],
[
1064,
25,
779
]
],
[
[
629,
24,
478
],
[
478,
25,
779
]
],
[
[
629,
25,
1377
],
[
1377,
... | [
[
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
],
[
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Clad... | Sirolimus may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may le... |
DB00705 | DB00773 | 441 | 896 | [
"DDInter496",
"DDInter702"
] | Delavirdine | Etoposide | A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitoti... | Minor | 0 | [
[
[
441,
23,
896
]
],
[
[
441,
6,
7524
],
[
7524,
45,
896
]
],
[
[
441,
21,
28681
],
[
28681,
60,
896
]
],
[
[
441,
64,
147
],
[
147,
... | [
[
[
"Delavirdine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Etoposide"
]
],
[
[
"Delavirdine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)",
... | Delavirdine (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Etoposide (Compound)
Delavirdine (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Etoposide (Compound)
Delavirdine may lead to a major life threatening interaction when taken with Vinblastine and Vin... |
DB00794 | DB09038 | 759 | 1,450 | [
"DDInter1521",
"DDInter636"
] | Primidone | Empagliflozin | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
759,
24,
1450
]
],
[
[
759,
24,
1486
],
[
1486,
24,
1450
]
],
[
[
759,
63,
870
],
[
870,
24,
1450
]
],
[
[
759,
25,
1017
],
[
1017,
... | [
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
],... | Primidone may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Primidone may cause a moderate interaction that could exacerbate diseases when taken with Flud... |
DB00575 | DB00687 | 1,020 | 870 | [
"DDInter412",
"DDInter747"
] | Clonidine | Fludrocortisone | Clonidine is an imidazole derivate that acts as an agonist of alpha-2 adrenoceptors. This activity is useful for the treatment of hypertension, severe pain, and ADHD.[L7237,L7240,L7243,L7246] Clonidine was granted FDA approval on 3 September 1974. | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Moderate | 1 | [
[
[
1020,
24,
870
]
],
[
[
1020,
24,
1220
],
[
1220,
40,
870
]
],
[
[
1020,
63,
251
],
[
251,
40,
870
]
],
[
[
1020,
21,
28936
],
[
28936,... | [
[
[
"Clonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
]
],
[
[
"Clonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
... | Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Fludrocortisone (Compound)
Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Fludroc... |
DB11652 | DB11986 | 1,155 | 484 | [
"DDInter1891",
"DDInter648"
] | Tucatinib | Entrectinib | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer w... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Major | 2 | [
[
[
1155,
25,
484
]
],
[
[
1155,
24,
466
],
[
466,
62,
484
]
],
[
[
1155,
64,
1135
],
[
1135,
23,
484
]
],
[
[
1155,
62,
222
],
[
222,
... | [
[
[
"Tucatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Entrectinib"
]
],
[
[
"Tucatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Darolutam... | Tucatinib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Tucatinib may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a... |
DB00570 | DB11834 | 147 | 1,303 | [
"DDInter1936",
"DDInter849"
] | Vinblastine | Guselkumab | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation . In clinical trials, guselkumab demonstra... | Moderate | 1 | [
[
[
147,
24,
1303
]
],
[
[
147,
63,
1461
],
[
1461,
23,
1303
]
],
[
[
147,
24,
949
],
[
949,
24,
1303
]
],
[
[
147,
63,
58
],
[
58,
... | [
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guselkumab"
]
],
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
... | Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Guselkumab
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxo... |
DB00794 | DB01611 | 759 | 1,487 | [
"DDInter1521",
"DDInter893"
] | Primidone | Hydroxychloroquine | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Moderate | 1 | [
[
[
759,
24,
1487
]
],
[
[
759,
21,
28658
],
[
28658,
60,
1487
]
],
[
[
759,
63,
723
],
[
723,
24,
1487
]
],
[
[
759,
64,
168
],
[
168,
... | [
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Primidone",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is ... | Primidone (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Hydroxychloroquine (Compound)
Primidone may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Hyd... |
DB00280 | DB01067 | 494 | 959 | [
"DDInter575",
"DDInter826"
] | Disopyramide | Glipizide | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Moderate | 1 | [
[
[
494,
24,
959
]
],
[
[
494,
63,
245
],
[
245,
40,
959
]
],
[
[
494,
24,
1411
],
[
1411,
1,
959
]
],
[
[
494,
6,
8374
],
[
8374,
4... | [
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
... | Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Glipizide (Comp... |
DB00342 | DB00526 | 1,181 | 1,555 | [
"DDInter1770",
"DDInter1355"
] | Terfenadine | Oxaliplatin | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Moderate | 1 | [
[
[
1181,
24,
1555
]
],
[
[
1181,
23,
1247
],
[
1247,
62,
1555
]
],
[
[
1181,
24,
79
],
[
79,
24,
1555
]
],
[
[
1181,
24,
479
],
[
479,
... | [
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
]
],
[
[
"Terfenadine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
... | Terfenadine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Oxaliplatin
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib ... |
DB00694 | DB06589 | 51 | 1,250 | [
"DDInter485",
"DDInter1400"
] | Daunorubicin | Pazopanib | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Moderate | 1 | [
[
[
51,
24,
1250
]
],
[
[
51,
6,
7950
],
[
7950,
45,
1250
]
],
[
[
51,
18,
4590
],
[
4590,
46,
1250
]
],
[
[
51,
7,
10440
],
[
10440,
... | [
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Daunorubicin",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound... | Daunorubicin (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Pazopanib (Compound)
Daunorubicin (Compound) downregulates RCHY1 (Gene) and RCHY1 (Gene) is upregulated by Pazopanib (Compound)
Daunorubicin (Compound) upregulates FUT1 (Gene) and FUT1 (Gene) is downregulated by Pazopanib (Compound)
Daunorubicin ... |
DB00818 | DB06595 | 898 | 1,491 | [
"DDInter1538",
"DDInter1214"
] | Propofol | Midostaurin | Propofol is an intravenous anaesthetic agent used for induction and maintenance of general anaesthesia. IV administration of propfol is used to induce unconsciousness after which anaesthesia may be maintained using a combination of medications. Recovery from propofol-induced anaesthesia is generally rapid and associate... | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Moderate | 1 | [
[
[
898,
24,
1491
]
],
[
[
898,
23,
112
],
[
112,
23,
1491
]
],
[
[
898,
63,
888
],
[
888,
24,
1491
]
],
[
[
898,
24,
1017
],
[
1017,
... | [
[
[
"Propofol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Propofol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Propofol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Propofol may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxife... |
DB00708 | DB06282 | 1,454 | 516 | [
"DDInter1718",
"DDInter1053"
] | Sufentanil | Levocetirizine | Sufentanil is an opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent. It is administered by the intravenous, epidural and sublingual routes. Also known as _Dsuvia_, the sublingual form is used for the management of acute pain in adults that is severe to w... | Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine. Levocetirizine was granted FDA approval in 1995. | Moderate | 1 | [
[
[
1454,
24,
516
]
],
[
[
1454,
63,
701
],
[
701,
24,
516
]
],
[
[
1454,
24,
407
],
[
407,
63,
516
]
],
[
[
1454,
24,
1219
],
[
1219,
... | [
[
[
"Sufentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Sufentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
... | Sufentanil may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Sufentanil may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium m... |
DB13139 | DB14568 | 1,032 | 982 | [
"DDInter1063",
"DDInter1000"
] | Levosalbutamol | Ivosidenib | Levosalbutamol, or levalbuterol, is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). [Salbutamol] has been marketed as a racemic mixture, although beta2-agonist activity resides almost exclusively in the (R)-enantiomer. The enantioselective ... | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Moderate | 1 | [
[
[
1032,
24,
982
]
],
[
[
1032,
63,
1559
],
[
1559,
24,
982
]
],
[
[
1032,
63,
11
],
[
11,
25,
982
]
],
[
[
1032,
64,
351
],
[
351,
... | [
[
[
"Levosalbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Levosalbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
],
... | Levosalbutamol may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Levosalbutamol may cause a moderate interaction that could exacerbate diseases when taken with Toremifene an... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.